1 hr. ago
Interested in Diversified Energy Company PLC? Here are five stocks we like better.
Diversified Energy agreed to acquire Birch Resources for approximately $1.8 billion, with closing expected in the fourth quarter of 2026. The deal would add 480 net wells, roughly 68,000 barrels of oil equivalent per day and 1.2 trillion cubic feet equivalent of reserves.
The acquisition would significantly expand Diversified's Permian presence, lifting production from about 9,000 to 77,000 barrels of oil equivalent per day and increasing projected Permian adjusted EBITDA from $64 million to $612 million. The ****** ets are about 70% liquids-weighted and include related infrastructure.
Diversified plans to finance the purchase mainly with ****** et-backed securities and expects operational synergies, while targeting nearly $2 billion of deleveraging over four years. The company said the transaction should increase total production by 35%, adjusted EBITDA by 55% and more than double free cash flow.
Premium Retail's Stress Test Is Separating Winners From Losers
#equivalent #energy #ebitda
Diversified Energy agreed to acquire Birch Resources for approximately $1.8 billion, with closing expected in the fourth quarter of 2026. The deal would add 480 net wells, roughly 68,000 barrels of oil equivalent per day and 1.2 trillion cubic feet equivalent of reserves.
The acquisition would significantly expand Diversified's Permian presence, lifting production from about 9,000 to 77,000 barrels of oil equivalent per day and increasing projected Permian adjusted EBITDA from $64 million to $612 million. The ****** ets are about 70% liquids-weighted and include related infrastructure.
Diversified plans to finance the purchase mainly with ****** et-backed securities and expects operational synergies, while targeting nearly $2 billion of deleveraging over four years. The company said the transaction should increase total production by 35%, adjusted EBITDA by 55% and more than double free cash flow.
Premium Retail's Stress Test Is Separating Winners From Losers
#equivalent #energy #ebitda
2 hours ago
Our ******* ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Nobody announces that they've stopped trusting you. They just start moving things out on weekday afternoons, a carload at a time, and by the time you notice, the good coat is already somewhere else. Central banks do this too but their subtle breaking up with you involves armored trucks, an ocean, and a press release that leans very hard on the word "logistics."
Between March and August, the Dutch central bank moved 86 tonnes of gold out of New York and Ottawa and into London. It called the project "crisis preparedness" and cited "increasing geopolitical unrest," which is central banker for saying the quiet part at a normal indoor volume.
De Nederlandsche Bank, DNB to its friends, closed 2025 sitting on 612.4 tonnes of gold worth €72.2 billion ($83.7 billion). About 31.3% of it lived in New York and another 19.7% in Ottawa, roughly 313 tonnes parked in North America. The 86 tonnes that left is a bit more than a quarter of that pile.
Roughly 59 tonnes never went anywhere at all. DNB sold that gold in New York and bought the same quantity in London, which is the bullion version of Venmo-ing a friend instead of driving across state lines with a duffel bag. The other 27-odd tonnes actually traveled, first from New York and Ottawa to DNB's own vault in the Dutch town of Zeist, then an equivalent amount from Zeist onward to London. The gold, in other words, flew with a layover. Structuring it that way let the bank skip melting down and re-casting bars to meet London's standards, which costs real money and carries the always-unwelcome risk of finishing the process with less gold than it started with.
#york #central #bank #roughly
Nobody announces that they've stopped trusting you. They just start moving things out on weekday afternoons, a carload at a time, and by the time you notice, the good coat is already somewhere else. Central banks do this too but their subtle breaking up with you involves armored trucks, an ocean, and a press release that leans very hard on the word "logistics."
Between March and August, the Dutch central bank moved 86 tonnes of gold out of New York and Ottawa and into London. It called the project "crisis preparedness" and cited "increasing geopolitical unrest," which is central banker for saying the quiet part at a normal indoor volume.
De Nederlandsche Bank, DNB to its friends, closed 2025 sitting on 612.4 tonnes of gold worth €72.2 billion ($83.7 billion). About 31.3% of it lived in New York and another 19.7% in Ottawa, roughly 313 tonnes parked in North America. The 86 tonnes that left is a bit more than a quarter of that pile.
Roughly 59 tonnes never went anywhere at all. DNB sold that gold in New York and bought the same quantity in London, which is the bullion version of Venmo-ing a friend instead of driving across state lines with a duffel bag. The other 27-odd tonnes actually traveled, first from New York and Ottawa to DNB's own vault in the Dutch town of Zeist, then an equivalent amount from Zeist onward to London. The gold, in other words, flew with a layover. Structuring it that way let the bank skip melting down and re-casting bars to meet London's standards, which costs real money and carries the always-unwelcome risk of finishing the process with less gold than it started with.
#york #central #bank #roughly
2 hours ago
On August 24, ePlus (NASDAQ:PLUS) announced it had completed the acquisition of the **** ets of Daymark Solutions, a Massachusetts-based IT services provider, with the deal having closed three days earlier on August 21. The announcement landed three weeks after the company posted first-quarter fiscal 2027 results on August 4, showing sales climbing even as profit slipped. Together, the two headlines capture where ePlus stands right now: reaching for new growth in cloud and security while working through pressure on its existing business.
Daymark, founded in 2001, built its business serving highly regulated, data-intensive industries including energy and utilities, healthcare, life sciences, defense, and financial services. Its core capabilities span modern data center infrastructure, cloud, Microsoft 365, Microsoft 365 Copilot, and cybersecurity, and its status as a Microsoft Tier 1 Cloud Solution Provider slots directly alongside ePlus' existing Azure and Microsoft 365 professional and managed services work. The acquisition also gives ePlus a deeper foothold in the New England region, particularly metropolitan Boston. CEO Mark Marron framed it as a way to gain a specialized Microsoft team that could serve as a catalyst for growth across Azure, Microsoft 365, security, and Copilot.
The timing lines up with what was already ePlus' fastest-growing segment. Managed services revenue rose 15.1% to $51.3 million in the first quarter, the segment's first quarter above $50 million, with gross profit up 11.3% on that growth. The balance sheet backs further moves like this one: cash and equivalents reached $448.9 million as of June 30, up from $410.8 million three months earlier, giving ePlus room for additional acquisitions, dividends, and buybacks. Management also pointed to record sales and a significant rise in booked and open orders, positioning the company for what it called a stronger second half.
The first quarter numbers show a company growing on top but shrinking underneath. Net earnings from continuing operations fell 5.4% to $30.3 million, adjusted EBITDA dropped 9.2% to $47.8 million, and operating income declined 9.6% to $38.8 million. Gross margin slipped to 23.3% from 23.9% a year earlier, with margin compression showing up across all three business segments rather than just one.
The professional services segment, the part of the business closest to the consulting and implementation work Daymark specializes in, fell 5.1% to $68.1 million, and its margin dropped to 36.9% from 39.2%. The product segment saw its own margin decline, to 21.0% from 21.3%, as an ongoing memory chip shortage extended lead times and delayed shipments. Terms of the Daymark transaction were not disclosed, leaving no visibility into what ePlus paid or how the deal affects near-term results.
#Microsoft #million #august #first
Daymark, founded in 2001, built its business serving highly regulated, data-intensive industries including energy and utilities, healthcare, life sciences, defense, and financial services. Its core capabilities span modern data center infrastructure, cloud, Microsoft 365, Microsoft 365 Copilot, and cybersecurity, and its status as a Microsoft Tier 1 Cloud Solution Provider slots directly alongside ePlus' existing Azure and Microsoft 365 professional and managed services work. The acquisition also gives ePlus a deeper foothold in the New England region, particularly metropolitan Boston. CEO Mark Marron framed it as a way to gain a specialized Microsoft team that could serve as a catalyst for growth across Azure, Microsoft 365, security, and Copilot.
The timing lines up with what was already ePlus' fastest-growing segment. Managed services revenue rose 15.1% to $51.3 million in the first quarter, the segment's first quarter above $50 million, with gross profit up 11.3% on that growth. The balance sheet backs further moves like this one: cash and equivalents reached $448.9 million as of June 30, up from $410.8 million three months earlier, giving ePlus room for additional acquisitions, dividends, and buybacks. Management also pointed to record sales and a significant rise in booked and open orders, positioning the company for what it called a stronger second half.
The first quarter numbers show a company growing on top but shrinking underneath. Net earnings from continuing operations fell 5.4% to $30.3 million, adjusted EBITDA dropped 9.2% to $47.8 million, and operating income declined 9.6% to $38.8 million. Gross margin slipped to 23.3% from 23.9% a year earlier, with margin compression showing up across all three business segments rather than just one.
The professional services segment, the part of the business closest to the consulting and implementation work Daymark specializes in, fell 5.1% to $68.1 million, and its margin dropped to 36.9% from 39.2%. The product segment saw its own margin decline, to 21.0% from 21.3%, as an ongoing memory chip shortage extended lead times and delayed shipments. Terms of the Daymark transaction were not disclosed, leaving no visibility into what ePlus paid or how the deal affects near-term results.
#Microsoft #million #august #first
2 hours ago
On August 3, Ethos Technologies (NASDAQ:LIFE) reported second-quarter results for the period ended June 30, showing revenue climbing 113% year over year to $189.6 million, the company's second straight quarter above triple-digit growth. Alongside the print, Ethos said its board had authorized a new $100 million buyback of its Class A common stock. For a life insurance technology company that only recently went public, doubling revenue while also committing fresh capital to share repurchases is the kind of combination that invites a closer look at what is actually driving the numbers underneath.
The top line breaks down into two channels moving at different speeds. Direct channel revenue grew 131% year over year to $116.5 million, which Ethos said came with similar unit economics to prior periods, while third-party revenue grew 90% to $73.1 million. Behind those dollars sits actual policy volume. Ethos activated 107,847 new policies in the quarter, up 133% year over year, extending past 100,000 added families in a single three-month stretch. Gross profit came in at $185.5 million, a 98% gross margin, showing that the underlying cost of writing each policy remains small relative to what it generates in revenue.
Cash generation kept pace too. The company produced $35.7 million in net cash from operations during the quarter and $66.9 million over the first six months of 2026, helping push its cash and cash equivalents balance to $112.2 million from $91.1 million at the end of 2025. Ethos also widened its product shelf, launching a Juvenile IUL policy in partnership with North American. Management's outlook points to more of the same: third-quarter revenue guidance of $160 million to $164 million implies 73% year-over-year growth at the midpoint, and full-year 2026 guidance calls for revenue between $727 million and $731 million, an 88% increase, alongside adjusted EBITDA of $119 million to $123 million for the year.
The strain shows up once the growth is measured against what actually reaches the bottom line. GAAP net income was $19.5 million, a 10% margin, barely above the $18.5 million Ethos earned in the same quarter a year ago despite revenue more than doubling in between. Contribution margin, which strips out sales and marketing costs, fell to 33% from 42% a year earlier. Adjusted EBITDA margin slipped to 19% from 23%, even though the EBITDA dollar figure itself grew to $35.2 million from $20.8 million. Revenue per activated policy fell 8% year over year to $1,758, which Ethos attributed to a shift in channel and product mix, meaning each new policy is worth less on average than it used to be.
#policy #Margin
The top line breaks down into two channels moving at different speeds. Direct channel revenue grew 131% year over year to $116.5 million, which Ethos said came with similar unit economics to prior periods, while third-party revenue grew 90% to $73.1 million. Behind those dollars sits actual policy volume. Ethos activated 107,847 new policies in the quarter, up 133% year over year, extending past 100,000 added families in a single three-month stretch. Gross profit came in at $185.5 million, a 98% gross margin, showing that the underlying cost of writing each policy remains small relative to what it generates in revenue.
Cash generation kept pace too. The company produced $35.7 million in net cash from operations during the quarter and $66.9 million over the first six months of 2026, helping push its cash and cash equivalents balance to $112.2 million from $91.1 million at the end of 2025. Ethos also widened its product shelf, launching a Juvenile IUL policy in partnership with North American. Management's outlook points to more of the same: third-quarter revenue guidance of $160 million to $164 million implies 73% year-over-year growth at the midpoint, and full-year 2026 guidance calls for revenue between $727 million and $731 million, an 88% increase, alongside adjusted EBITDA of $119 million to $123 million for the year.
The strain shows up once the growth is measured against what actually reaches the bottom line. GAAP net income was $19.5 million, a 10% margin, barely above the $18.5 million Ethos earned in the same quarter a year ago despite revenue more than doubling in between. Contribution margin, which strips out sales and marketing costs, fell to 33% from 42% a year earlier. Adjusted EBITDA margin slipped to 19% from 23%, even though the EBITDA dollar figure itself grew to $35.2 million from $20.8 million. Revenue per activated policy fell 8% year over year to $1,758, which Ethos attributed to a shift in channel and product mix, meaning each new policy is worth less on average than it used to be.
#policy #Margin
3 hours ago
On August 4, Innospec (NASDAQ:IOSP) reported second-quarter results that pushed revenue up 12% to $491.4 million, with every one of its three businesses posting higher operating income. Net income attributable to Innospec climbed to $30.8 million, or $1.25 per diluted share, up from $23.5 million and 94 cents a year earlier. That headline growth was real, but a look further down the cash flow statement shows a business generating far less cash than its earnings suggest, a gap investors weighing this specialty chemicals maker need to understand.
Every segment expanded in the quarter ended June 30. Performance Chemicals revenue rose 9% to $190.3 million, with operating income up 15% to $16.4 million as price and mix gains of 8% more than offset a 2% drop in volumes. Fuel Specialties, the company's largest and most profitable unit, grew revenue 12% to $185.7 million on a 7% volume increase, with margins staying inside management's target range even as the business absorbed input cost pressure.
Oilfield Services put up the sharpest turnaround. Revenue jumped 14% to $115.4 million, gross margin expanded 2.7 percentage points to 32.3%, and operating income surged 40% to $8.7 million, a swing the company tied to its recent DRA plant expansion. That kind of margin recovery in a smaller segment can move the needle disproportionately if it continues.
Underneath all of it sits a debt-free balance sheet with $250.2 million in net cash. Innospec used part of that cushion to pay its semi-annual dividend of 92 cents per share and repurchase 87,089 shares for $6.4 million in the quarter, continuing a pattern of returning cash to shareholders without adding leverage.
The cash flow statement tells a less flattering story. Operating cash flow for the first six months of 2026 fell to $24.8 million from $38.8 million a year earlier, as working capital changes consumed $60.9 million compared with $22.6 million in the prior-year period. Cash and equivalents dropped to $250.2 million at quarter-end from $292.5 million at the start of the year, even before the dividend and buybacks funded from that balance are counted.
#million #quarter #flow #every
Every segment expanded in the quarter ended June 30. Performance Chemicals revenue rose 9% to $190.3 million, with operating income up 15% to $16.4 million as price and mix gains of 8% more than offset a 2% drop in volumes. Fuel Specialties, the company's largest and most profitable unit, grew revenue 12% to $185.7 million on a 7% volume increase, with margins staying inside management's target range even as the business absorbed input cost pressure.
Oilfield Services put up the sharpest turnaround. Revenue jumped 14% to $115.4 million, gross margin expanded 2.7 percentage points to 32.3%, and operating income surged 40% to $8.7 million, a swing the company tied to its recent DRA plant expansion. That kind of margin recovery in a smaller segment can move the needle disproportionately if it continues.
Underneath all of it sits a debt-free balance sheet with $250.2 million in net cash. Innospec used part of that cushion to pay its semi-annual dividend of 92 cents per share and repurchase 87,089 shares for $6.4 million in the quarter, continuing a pattern of returning cash to shareholders without adding leverage.
The cash flow statement tells a less flattering story. Operating cash flow for the first six months of 2026 fell to $24.8 million from $38.8 million a year earlier, as working capital changes consumed $60.9 million compared with $22.6 million in the prior-year period. Cash and equivalents dropped to $250.2 million at quarter-end from $292.5 million at the start of the year, even before the dividend and buybacks funded from that balance are counted.
#million #quarter #flow #every
3 hours ago
On August 13, Kodiak Sciences Inc. (NASDAQ:KOD) reported second-quarter financial results for the period ended June 30, alongside an update on its three late-stage eye disease programs. The clinical-stage biotech told investors it now sits within months of three separate Phase 3 readouts, a stretch CEO Victor Perlroth called the payoff of years of disciplined execution. For a company with no approved products and a widening cash burn, those trial results are about to decide a lot.
Kodiak's near-term story rests on Zenkuda and KSI-501, both being tested in the Phase 3 DAYBREAK study for treatment-naive wet age-related macular degeneration, with one-year primary endpoint topline data due in September 2026. Zenkuda already has four completed Phase 3 studies behind it. In GLOW1 and GLOW2, every patient remained on extended six-month dosing at one year, and in BEACON, nearly half of Zenkuda patients needed no further treatment in the second six months while matching aflibercept on vision and anatomical outcomes. That durability comes from a mean ocular half-life of 20 days, roughly three times longer than approved anti-VEGF drugs.
Behind DAYBREAK sits PEAK, evaluating KSI-101 in macular edema secondary to inflammation, where Kodiak finished enrolling the first 300-patient cohort during the quarter and expects Pivotal ***** ysis 1 data in December 2026. Earlier Phase 1b data showed more than half of MESI patients gaining at least 15 letters of vision, with over 90% resolution of retinal fluid by week eight. Kodiak also began enrolling patients in the roughly 910-patient ALTO study testing KSI-501 against aflibercept in diabetic macular edema, its second registrational trial for that molecule. Zenkuda and KSI-501 together are aimed at a $15 billion anti-VEGF market.
None of that comes cheap. Kodiak's net loss widened to $65.6 million in the second quarter of 2026, or $1.05 per share, up from $54.3 million and $1.03 per share a year earlier. R&D spending jumped to $56.1 million from $42.8 million, as the company ramped up clinical activity across PEAK and PINNACLE and stepped up manufacturing for its Phase 3 programs. General and administrative costs eased slightly to $10.8 million from $12.8 million, but that was not enough to offset the R&D increase.
Kodiak ended the quarter with $125.9 million in cash and equivalents, which management says covers operations into 2027, but working capital fell from $169.3 million at the end of 2025 to $78.6 million by June 30, and stockholders' equity dropped from $157.4 million to $61.1 million over the same stretch. With three separate trials due to report between September and December, any delay or disappointing result would hit a balance sheet that already has less room to absorb it.
#data
Kodiak's near-term story rests on Zenkuda and KSI-501, both being tested in the Phase 3 DAYBREAK study for treatment-naive wet age-related macular degeneration, with one-year primary endpoint topline data due in September 2026. Zenkuda already has four completed Phase 3 studies behind it. In GLOW1 and GLOW2, every patient remained on extended six-month dosing at one year, and in BEACON, nearly half of Zenkuda patients needed no further treatment in the second six months while matching aflibercept on vision and anatomical outcomes. That durability comes from a mean ocular half-life of 20 days, roughly three times longer than approved anti-VEGF drugs.
Behind DAYBREAK sits PEAK, evaluating KSI-101 in macular edema secondary to inflammation, where Kodiak finished enrolling the first 300-patient cohort during the quarter and expects Pivotal ***** ysis 1 data in December 2026. Earlier Phase 1b data showed more than half of MESI patients gaining at least 15 letters of vision, with over 90% resolution of retinal fluid by week eight. Kodiak also began enrolling patients in the roughly 910-patient ALTO study testing KSI-501 against aflibercept in diabetic macular edema, its second registrational trial for that molecule. Zenkuda and KSI-501 together are aimed at a $15 billion anti-VEGF market.
None of that comes cheap. Kodiak's net loss widened to $65.6 million in the second quarter of 2026, or $1.05 per share, up from $54.3 million and $1.03 per share a year earlier. R&D spending jumped to $56.1 million from $42.8 million, as the company ramped up clinical activity across PEAK and PINNACLE and stepped up manufacturing for its Phase 3 programs. General and administrative costs eased slightly to $10.8 million from $12.8 million, but that was not enough to offset the R&D increase.
Kodiak ended the quarter with $125.9 million in cash and equivalents, which management says covers operations into 2027, but working capital fell from $169.3 million at the end of 2025 to $78.6 million by June 30, and stockholders' equity dropped from $157.4 million to $61.1 million over the same stretch. With three separate trials due to report between September and December, any delay or disappointing result would hit a balance sheet that already has less room to absorb it.
#data
3 hours ago
On August 6, Dentsply Sirona (NASDAQ:XRAY) reported second-quarter 2026 results that pulled the stock in two directions at once. Net sales fell 4.1% year over year to $898 million, yet the company swung from a $45 million net loss a year earlier to $37 million in net income, with diluted earnings per share of $0.18 versus a $0.22 loss. Investors are left weighing a real profitability turnaround against a top line that is still shrinking.
GAAP gross margin climbed to 54.9% from 52.4% a year ago, and adjusted gross margin came in at 56.4%. Adjusted EBITDA margin ticked up slightly to 21.3% from 21.1%. Cash generation improved even more sharply. Operating cash flow jumped to $99 million from $48 million in the second quarter of 2025, helped by roughly $44 million in tariff refunds along with tighter management of inventory and payables. Free cash flow more than tripled to $55 million from $16 million. The company used some of that cash to repurchase 1.3 million shares for about $12 million during the quarter, and it also expanded its partnership with Medline Sinclair to broaden access to its Connected Technology Solutions portfolio across Canada.
Wellspect Healthcare was the lone segment posting real growth, with net sales up 7.1% to $86 million, and EMEA sales as reported were essentially flat at 0.2% growth. There were no goodwill or intangible ***** et impairments this quarter, a contrast to the $235 million charge taken in the same period last year. Despite the sales decline, the company reiterated its full-year 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
The headline sales decline understates the underlying softness. On a constant currency basis, net sales fell 6.3%, meaning currency translation actually flattered the reported number. Orthodontic and Implant Solutions was the weakest segment, with sales dropping 13.2% to $197 million from $226 million a year ago. The Americas region fared worst geographically, with net sales down 10.7% as reported and 11.6% in constant currency.
Even the adjusted numbers show cracks: adjusted EPS of $0.52 was actually down 1.6% from a year earlier, despite the improved GAAP figures. The balance sheet tightened too, with cash and equivalents falling to $239 million from $326 million at the end of 2025, against long-term debt of nearly $2 billion. Restructuring and other costs for the first six months of 2026 totaled $69 million, up sharply from $13 million in the same period a year ago, tied in part to costs from a new global ERP system.
#year #company
GAAP gross margin climbed to 54.9% from 52.4% a year ago, and adjusted gross margin came in at 56.4%. Adjusted EBITDA margin ticked up slightly to 21.3% from 21.1%. Cash generation improved even more sharply. Operating cash flow jumped to $99 million from $48 million in the second quarter of 2025, helped by roughly $44 million in tariff refunds along with tighter management of inventory and payables. Free cash flow more than tripled to $55 million from $16 million. The company used some of that cash to repurchase 1.3 million shares for about $12 million during the quarter, and it also expanded its partnership with Medline Sinclair to broaden access to its Connected Technology Solutions portfolio across Canada.
Wellspect Healthcare was the lone segment posting real growth, with net sales up 7.1% to $86 million, and EMEA sales as reported were essentially flat at 0.2% growth. There were no goodwill or intangible ***** et impairments this quarter, a contrast to the $235 million charge taken in the same period last year. Despite the sales decline, the company reiterated its full-year 2026 outlook of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
The headline sales decline understates the underlying softness. On a constant currency basis, net sales fell 6.3%, meaning currency translation actually flattered the reported number. Orthodontic and Implant Solutions was the weakest segment, with sales dropping 13.2% to $197 million from $226 million a year ago. The Americas region fared worst geographically, with net sales down 10.7% as reported and 11.6% in constant currency.
Even the adjusted numbers show cracks: adjusted EPS of $0.52 was actually down 1.6% from a year earlier, despite the improved GAAP figures. The balance sheet tightened too, with cash and equivalents falling to $239 million from $326 million at the end of 2025, against long-term debt of nearly $2 billion. Restructuring and other costs for the first six months of 2026 totaled $69 million, up sharply from $13 million in the same period a year ago, tied in part to costs from a new global ERP system.
#year #company
3 hours ago
By Mike Dolan
Sept 3 (Reuters) - Some calm has returned to world markets over the past 24 hours as oil prices steadied and the angry bond market cooled down a bit.
There were no breakthroughs in the Gulf standoff between the U.S. and Iran, but President Donald Trump indicated an intention to limit the duration of the latest round of attacks, and top aides are seeking "quiet" in the conflict ahead of November's midterm elections.
U.S. Treasury yields eased from multi-year highs overnight, while European equivalents remained on edge due to an exceptional surge in natural gas prices to three-year highs ahead of the winter season.
In equities, Asian shares were choppy on Thursday, while Wall Street futures were up before the bell after major indexes stateside closed higher on Wednesday.
#prices #year #highs #gulf
Sept 3 (Reuters) - Some calm has returned to world markets over the past 24 hours as oil prices steadied and the angry bond market cooled down a bit.
There were no breakthroughs in the Gulf standoff between the U.S. and Iran, but President Donald Trump indicated an intention to limit the duration of the latest round of attacks, and top aides are seeking "quiet" in the conflict ahead of November's midterm elections.
U.S. Treasury yields eased from multi-year highs overnight, while European equivalents remained on edge due to an exceptional surge in natural gas prices to three-year highs ahead of the winter season.
In equities, Asian shares were choppy on Thursday, while Wall Street futures were up before the bell after major indexes stateside closed higher on Wednesday.
#prices #year #highs #gulf
10 hours ago
We're closing one of our most-requested cross-platform gaps.
Android now gets continuously-updating live updates on the lock screen as ongoing notifications, Android's equivalent of iOS Live Activities and Apple's Dynamic Island. For Fantasy on Android, this is the first time you'll get persistent, real-time updates as your matchup plays out.
Android live updates. (Photo by Carrie Anderson/Yahoo Sports)
iOS gets an upgrade, too. Live Activities on the Yahoo Sports app now include the drive chart, so you can follow every play of a drive in real time without ever leaving your lock screen.
iOS gets an upgrade, too. (Photo by Carrie Anderson/Yahoo Sports)
#live #time #lock
Android now gets continuously-updating live updates on the lock screen as ongoing notifications, Android's equivalent of iOS Live Activities and Apple's Dynamic Island. For Fantasy on Android, this is the first time you'll get persistent, real-time updates as your matchup plays out.
Android live updates. (Photo by Carrie Anderson/Yahoo Sports)
iOS gets an upgrade, too. Live Activities on the Yahoo Sports app now include the drive chart, so you can follow every play of a drive in real time without ever leaving your lock screen.
iOS gets an upgrade, too. (Photo by Carrie Anderson/Yahoo Sports)
#live #time #lock
15 hours ago
Shell has completed its acquisition of Canadian oil and gas producer ARC Resources, significantly expanding the supermajor's position in the prolific Montney basin of British Columbia and Alberta.
The transaction has an updated enterprise value of approximately $16.5 billion, including $2.5 billion of net debt and leases. ARC shareholders receive C$8.20 in cash and 0.40247 Shell shares for each ARC share, according to Shell.
The acquisition immediately adds around 370,000 barrels of oil equivalent per day of natural gas and liquids production to Shell's portfolio and more than 1.5 million net acres in the Montney. At the end of 2025, ARC held around 2 billion boe of proved and probable reserves.
The deal also strengthens Shell's Canadian LNG strategy. ARC's gas resources sit close to Shell's existing Montney operations, while Shell owns a 40% interest in LNG Canada. ARC previously said its undeveloped gas properties could help Shell extract additional value through its integrated LNG business, including a potential second phase of LNG Canada.
Shell expects the acquisition to lift production growth across its Integrated Gas and Upstream businesses to around 4% annually through 2030, compared with 2025. The company expects double-digit returns and says the deal should boost free cash flow per share beginning in 2027.
#acquisition #canadian #resources
The transaction has an updated enterprise value of approximately $16.5 billion, including $2.5 billion of net debt and leases. ARC shareholders receive C$8.20 in cash and 0.40247 Shell shares for each ARC share, according to Shell.
The acquisition immediately adds around 370,000 barrels of oil equivalent per day of natural gas and liquids production to Shell's portfolio and more than 1.5 million net acres in the Montney. At the end of 2025, ARC held around 2 billion boe of proved and probable reserves.
The deal also strengthens Shell's Canadian LNG strategy. ARC's gas resources sit close to Shell's existing Montney operations, while Shell owns a 40% interest in LNG Canada. ARC previously said its undeveloped gas properties could help Shell extract additional value through its integrated LNG business, including a potential second phase of LNG Canada.
Shell expects the acquisition to lift production growth across its Integrated Gas and Upstream businesses to around 4% annually through 2030, compared with 2025. The company expects double-digit returns and says the deal should boost free cash flow per share beginning in 2027.
#acquisition #canadian #resources
20 hours ago
Our ******* ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Michael Dell went on X Tuesday night and posted this: "There's an old Texas saying I may have just made up... If you keep growing EPS 200%+ y/y something good will happen."
He has earned the right to make up sayings. Dell reported $7.04 in adjusted earnings against the $4.92 Wall Street wanted, on revenue of $46.97 billion against $44.92 billion. Revenue grew 58% and beat every estimate on the street. Net income went from $1.16 billion a year ago to $4.13 billion. Shares rose 9% after hours, on top of a stock up 236% this year against the S&P's 11%.
Then Dell said what next quarter looks like, which is where it stops being a good print and starts being ridiculous. Third-quarter guidance came in at $6.50 a share on $49 billion, implying 81% growth. ******* ysts had penciled in $4.49 and $41.42 billion. Dell guided $7.6 billion above consensus for one quarter, more revenue than most S&P 500 companies book in a year.
The full-year number is the one to sit with. Dell now sees $25.50 in adjusted EPS on $192 billion of revenue. In May, it said $17.90 on $165 billion to $169 billion. Over 3 months, Dell added roughly $25 billion of expected revenue and 42% to its own earnings forecast, the corporate equivalent of checking the couch cushions and finding a Honda Accord.
#Stock
Michael Dell went on X Tuesday night and posted this: "There's an old Texas saying I may have just made up... If you keep growing EPS 200%+ y/y something good will happen."
He has earned the right to make up sayings. Dell reported $7.04 in adjusted earnings against the $4.92 Wall Street wanted, on revenue of $46.97 billion against $44.92 billion. Revenue grew 58% and beat every estimate on the street. Net income went from $1.16 billion a year ago to $4.13 billion. Shares rose 9% after hours, on top of a stock up 236% this year against the S&P's 11%.
Then Dell said what next quarter looks like, which is where it stops being a good print and starts being ridiculous. Third-quarter guidance came in at $6.50 a share on $49 billion, implying 81% growth. ******* ysts had penciled in $4.49 and $41.42 billion. Dell guided $7.6 billion above consensus for one quarter, more revenue than most S&P 500 companies book in a year.
The full-year number is the one to sit with. Dell now sees $25.50 in adjusted EPS on $192 billion of revenue. In May, it said $17.90 on $165 billion to $169 billion. Over 3 months, Dell added roughly $25 billion of expected revenue and 42% to its own earnings forecast, the corporate equivalent of checking the couch cushions and finding a Honda Accord.
#Stock
1 day ago
From my own Bears-centric view of things, the Chicago Bears under Ryan Poles seem to have had a pretty rare set of conditions to help usher along a rebuild. In his first five years on the job, Poles had four selections in the top third of the first round (i.e. Top 11 picks) including the #1 overall pick. He also made nine eight selections in the Top 50, and seventeen selections in the Top 100. How many GMs have enjoyed that much opportunity?
Well, it depends. Obviously, the selections needed to be available under the same general manager. This excludes teams like Cleveland, which had back-to-back #1 selections in 2017 (Garrett) and 2018 (Mayfield) and seven top-ten picks in just nine years–but that was under six different managers. It also excludes Nick Cesario of Houston Texans, who would put up a good show but who only has three picks in the top eleven, even if all those were made within the top three. Likewise, if the sticking point is four elite selections, Trent Baalke doesn't count either. He made back-to-back selections with the #1 overall pick (Lawrence and Walker), and despite having more pricey premium picks on a per-year basis than Poles (averaging 2,581 points on the Jimmy Johnson chart just in his four years, or the equivalent of having the #4 spot in the draft for four straight years), he didn't qualify because his tenure was too short.
Also not included, even though he would technically qualify, is Les Snead. He did in fact have four elite picks (and the #13 selection he used on Aaron Donald) in a 4-year stretch, but I intend on doing a larger piece later in the season looking at exactly how the Rams have defied convention on so many different fronts. For now, though, here are the other nine in ascending order of Top 11 draft picks made, with ties broken by average value of top picks made.
Licht needed seven years to reach the playoffs, but when he got his team there, they won it all. His first six years averaged 2,358 points of premium draft selections per year and a .34 win rate, meaning he had more to work with but worse results than Poles has had to date. Of course, that championship the next year covers a lot.
Key Selections: 4/18/31, meaning that he had 4 picks in the top eleven, 18 picks in the top fifty, and 31 in the first three rounds* with 19,457 in premium picks (1,621 per year) over his 12-year career.
#picks #four #first #nine
Well, it depends. Obviously, the selections needed to be available under the same general manager. This excludes teams like Cleveland, which had back-to-back #1 selections in 2017 (Garrett) and 2018 (Mayfield) and seven top-ten picks in just nine years–but that was under six different managers. It also excludes Nick Cesario of Houston Texans, who would put up a good show but who only has three picks in the top eleven, even if all those were made within the top three. Likewise, if the sticking point is four elite selections, Trent Baalke doesn't count either. He made back-to-back selections with the #1 overall pick (Lawrence and Walker), and despite having more pricey premium picks on a per-year basis than Poles (averaging 2,581 points on the Jimmy Johnson chart just in his four years, or the equivalent of having the #4 spot in the draft for four straight years), he didn't qualify because his tenure was too short.
Also not included, even though he would technically qualify, is Les Snead. He did in fact have four elite picks (and the #13 selection he used on Aaron Donald) in a 4-year stretch, but I intend on doing a larger piece later in the season looking at exactly how the Rams have defied convention on so many different fronts. For now, though, here are the other nine in ascending order of Top 11 draft picks made, with ties broken by average value of top picks made.
Licht needed seven years to reach the playoffs, but when he got his team there, they won it all. His first six years averaged 2,358 points of premium draft selections per year and a .34 win rate, meaning he had more to work with but worse results than Poles has had to date. Of course, that championship the next year covers a lot.
Key Selections: 4/18/31, meaning that he had 4 picks in the top eleven, 18 picks in the top fifty, and 31 in the first three rounds* with 19,457 in premium picks (1,621 per year) over his 12-year career.
#picks #four #first #nine
1 day ago
By Ankur Banerjee, Harry Robertson and Laura Matthews
SINGAPORE/LONDON/NEW YORK, Sept 2 (Reuters) - Bond prices continued to slide in Asia and Europe on Wednesday, pushing borrowing costs to multi-decade highs as the Middle East conflict drives up energy prices and layers concerns about inflation on top of worries about ballooning government debt.
Sovereign bond yields are a reference point for ******* et prices across financial markets and the higher price of money means elevated mortgage rates for consumers and tough choices for government spending as funding costs climb.
Japan's 10-year yield was perched above 3% for the first time in 30 years, while rising gas prices meant German 10-year Bund yields were stuck at their highest since 2011 and Britain's equivalent was at its highest since 2008. Yields rise as prices fall and vice versa.
A confluence of factors was at play, said State Street's head of macro strategy, Michael Metcalfe, with rising energy prices causing traders to bet on rate hikes, pushing up short-dated yields.
#prices #yields #bond #costs
SINGAPORE/LONDON/NEW YORK, Sept 2 (Reuters) - Bond prices continued to slide in Asia and Europe on Wednesday, pushing borrowing costs to multi-decade highs as the Middle East conflict drives up energy prices and layers concerns about inflation on top of worries about ballooning government debt.
Sovereign bond yields are a reference point for ******* et prices across financial markets and the higher price of money means elevated mortgage rates for consumers and tough choices for government spending as funding costs climb.
Japan's 10-year yield was perched above 3% for the first time in 30 years, while rising gas prices meant German 10-year Bund yields were stuck at their highest since 2011 and Britain's equivalent was at its highest since 2008. Yields rise as prices fall and vice versa.
A confluence of factors was at play, said State Street's head of macro strategy, Michael Metcalfe, with rising energy prices causing traders to bet on rate hikes, pushing up short-dated yields.
#prices #yields #bond #costs
1 day ago
On August 3, The Andersons Inc. (NASDAQ:ANDE) reported second-quarter results that dwarfed last year's numbers, with net income attributable to the company climbing to $57 million, or $1.65 per diluted share, from just $7.9 million, or $0.23 per share, a year earlier. Adjusted net income reached $74 million, or $2.15 per share, versus $8.4 million, or $0.24 per share, in the second quarter of 2025. The turnaround leaned almost entirely on one business: renewable fuels.
Renewables did the heavy lifting. The segment posted a record second-quarter pretax income of $65 million, with the adjusted figure reaching $88 million, on record plant output and strong merchandising execution. Andersons credited its low-carbon strategy for $24 million in 45Z producer tax credits during the quarter, plus the first-quarter finalization of the Renewable Volume Obligations, which firmed up commodity markets and opened trading opportunities for the merchandising desk. Gains in distillers corn oil and RIN pricing also helped. Segment adjusted EBITDA came in at $103 million, more than triple the $30 million posted a year earlier.
Agribusiness improved too, if more modestly, with pretax income of $20 million, both on a GAAP and adjusted basis, up from $17 million in the prior-year quarter. Fertilizer margins strengthened even as volumes fell, and merchandising benefited from higher commodity prices and early-quarter volatility. The company is pushing further into low-carbon fuels, preparing a debottlenecking project at its Clymers, Indiana ethanol plant and advancing a Class VI well permit to capture more 45Z value. A new soybean meal export operation at the Port of Houston is expected online in the fourth quarter. Operating cash flow of $488 million for the quarter, up from $299 million a year earlier, gave the company room to keep funding those projects while holding long-term debt to EBITDA below its 2.5-times target.
The numbers come with caveats. Cash and cash equivalents stood at just $66.5 million at the end of the second quarter, down from $351 million a year earlier, even as short-term debt climbed to $314 million from $104 million. Much of that swing traces to working capital timing and investment spending rather than distress, but it leaves less cushion than the company carried a year ago.
In Agribusiness, the fertilizer and merchandising gains were partly offset by fuel surcharges, a reminder that the segment's profitability still moves with input costs it does not control. Andersons also warned that a drier stretch across its western growing regions could weigh on grain-asset profits this fall, even though better conditions in the eastern corn belt cut the other way, and that grower economics could limit fertilizer purchasing heading into the fall application season.
#million #year #income #Share
Renewables did the heavy lifting. The segment posted a record second-quarter pretax income of $65 million, with the adjusted figure reaching $88 million, on record plant output and strong merchandising execution. Andersons credited its low-carbon strategy for $24 million in 45Z producer tax credits during the quarter, plus the first-quarter finalization of the Renewable Volume Obligations, which firmed up commodity markets and opened trading opportunities for the merchandising desk. Gains in distillers corn oil and RIN pricing also helped. Segment adjusted EBITDA came in at $103 million, more than triple the $30 million posted a year earlier.
Agribusiness improved too, if more modestly, with pretax income of $20 million, both on a GAAP and adjusted basis, up from $17 million in the prior-year quarter. Fertilizer margins strengthened even as volumes fell, and merchandising benefited from higher commodity prices and early-quarter volatility. The company is pushing further into low-carbon fuels, preparing a debottlenecking project at its Clymers, Indiana ethanol plant and advancing a Class VI well permit to capture more 45Z value. A new soybean meal export operation at the Port of Houston is expected online in the fourth quarter. Operating cash flow of $488 million for the quarter, up from $299 million a year earlier, gave the company room to keep funding those projects while holding long-term debt to EBITDA below its 2.5-times target.
The numbers come with caveats. Cash and cash equivalents stood at just $66.5 million at the end of the second quarter, down from $351 million a year earlier, even as short-term debt climbed to $314 million from $104 million. Much of that swing traces to working capital timing and investment spending rather than distress, but it leaves less cushion than the company carried a year ago.
In Agribusiness, the fertilizer and merchandising gains were partly offset by fuel surcharges, a reminder that the segment's profitability still moves with input costs it does not control. Andersons also warned that a drier stretch across its western growing regions could weigh on grain-asset profits this fall, even though better conditions in the eastern corn belt cut the other way, and that grower economics could limit fertilizer purchasing heading into the fall application season.
#million #year #income #Share
2 days ago
The awards have been handed out!
The Gran Gala del Calcio 2026 took place in Milan on Wednesday night. It is the Italian equivalent of France's UNFP Trophies, a ceremony that hands out individual awards in recognition of the season that has just ended.
This year, the Serie A Player of the Year award went to Federico Dimarco. After an outstanding league campaign with seven goals and 18 ****** ists, the Italian full-back led Inter Milan to the Serie A ****** le.
In addition, Cesc Fabregas and Nico Paz were named Coach of the Year and Young Player of the Year respectively, following their superb 2025-26 season that saw Como qualify for the Champions League.
Check out the full list of the evening's awards below:
#awards #Milan #full
The Gran Gala del Calcio 2026 took place in Milan on Wednesday night. It is the Italian equivalent of France's UNFP Trophies, a ceremony that hands out individual awards in recognition of the season that has just ended.
This year, the Serie A Player of the Year award went to Federico Dimarco. After an outstanding league campaign with seven goals and 18 ****** ists, the Italian full-back led Inter Milan to the Serie A ****** le.
In addition, Cesc Fabregas and Nico Paz were named Coach of the Year and Young Player of the Year respectively, following their superb 2025-26 season that saw Como qualify for the Champions League.
Check out the full list of the evening's awards below:
#awards #Milan #full
4 days ago
PetroChina reported record first-half operating results for 2026, with profit attributable to shareholders rising 22% year over year to RMB103.94 billion as the Chinese energy giant expanded across natural gas, new materials and lower-carbon businesses.
Revenue increased 5.3% to RMB1.527 trillion, while basic earnings per share reached RMB0.57. PetroChina said it was the first time its attributable profit had exceeded RMB100 billion in a half-year period.
The company's oil, gas and new energies business remained its biggest earnings contributor, generating RMB100.45 billion in operating profit during the first half.
PetroChina reported oil and gas equivalent production of 921 million barrels, domestic crude production of 393 million barrels and marketable natural gas production of 2.66 trillion cubic feet.
The company said it made six new discoveries and advanced 19 new developments during the period. It also established two large gas reserve areas in the Sichuan and Junggar basins and a major deep conventional oil reserve area at Tarim Fuman.
#petrochina #first #production #rmb100
Revenue increased 5.3% to RMB1.527 trillion, while basic earnings per share reached RMB0.57. PetroChina said it was the first time its attributable profit had exceeded RMB100 billion in a half-year period.
The company's oil, gas and new energies business remained its biggest earnings contributor, generating RMB100.45 billion in operating profit during the first half.
PetroChina reported oil and gas equivalent production of 921 million barrels, domestic crude production of 393 million barrels and marketable natural gas production of 2.66 trillion cubic feet.
The company said it made six new discoveries and advanced 19 new developments during the period. It also established two large gas reserve areas in the Sichuan and Junggar basins and a major deep conventional oil reserve area at Tarim Fuman.
#petrochina #first #production #rmb100
5 days ago
OpenAI revoked Cursor's API access after **** eX's $60 billion acquisition, citing Musk's pattern of contract violations, though OpenAI served just 5% of traffic.
SpaceX's Colossus clusters, targeting 1 million H100 equivalents, now power Cursor's $4 billion revenue base, eliminating dependence on rival AI suppliers.
Analysts set a $219 average price target on **** eX, representing over 50% upside, as AI vertical integration mirrors the playbook that collapsed launch costs.
Act now: the **** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and **** eX didn't make the cut. Grab the names FREE today.
The long-running dispute between OpenAI CEO Sam Altman and Elon Musk has simmered for years, rooted in Musk's exit from the AI lab he co-founded and his subsequent legal and public challenges over its direction. That rivalry just moved from boardroom barbs to operational consequences.
#openai #grab #altman
SpaceX's Colossus clusters, targeting 1 million H100 equivalents, now power Cursor's $4 billion revenue base, eliminating dependence on rival AI suppliers.
Analysts set a $219 average price target on **** eX, representing over 50% upside, as AI vertical integration mirrors the playbook that collapsed launch costs.
Act now: the **** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and **** eX didn't make the cut. Grab the names FREE today.
The long-running dispute between OpenAI CEO Sam Altman and Elon Musk has simmered for years, rooted in Musk's exit from the AI lab he co-founded and his subsequent legal and public challenges over its direction. That rivalry just moved from boardroom barbs to operational consequences.
#openai #grab #altman
6 days ago
On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do. Jim Cramer replied:
Here's what I would do: I think that you have to take a little bit off. But I have also, because of my daughter who had melanoma and fortunately beat it, done a huge amount of work on the vaccine, and I got to tell you, I would hold on to this stock because I think the vaccine is very for real.
Moderna shares surged 177% on August 19 after the company and Merck & Co. announced that their personalized mRNA cancer vaccine, intismeran autogene, met the primary and key secondary endpoints in a Phase 3 melanoma trial involving 1,137 patients. The result gives Moderna its strongest late-stage evidence yet that its mRNA platform can work as a therapeutic cancer treatment. However, the detailed Phase 3 data have not been released, and investors should not confuse the new results with the 49% reduction in recurrence or death and 59% reduction in distant metastasis or death reported in the earlier Phase 2b study.
The clinical breakthrough arrived well before Moderna, Inc.'s (NASDAQ:MRNA) financial turnaround. The company generated $145 million of second-quarter 2026 revenue and reported a $782 million GAAP net loss, while continuing to target cash breakeven in 2028. It ended June with $6.9 billion of cash, cash equivalents, and investments, although it subsequently paid $950 million related to a litigation settlement.
The bear argument is that Moderna, Inc.'s (NASDAQ:MRNA) stock has repriced faster than the fundamental business has been proven. Its market value increased by tens of billions of dollars following the announcement of a trial whose detailed Phase 3 data remain outstanding. Regulatory approval is still required, while personalized cancer vaccines must overcome significant manufacturing and logistical challenges. Success in melanoma also does not guarantee comparable results in lung, bladder, kidney, or other cancers.
#mrna
Here's what I would do: I think that you have to take a little bit off. But I have also, because of my daughter who had melanoma and fortunately beat it, done a huge amount of work on the vaccine, and I got to tell you, I would hold on to this stock because I think the vaccine is very for real.
Moderna shares surged 177% on August 19 after the company and Merck & Co. announced that their personalized mRNA cancer vaccine, intismeran autogene, met the primary and key secondary endpoints in a Phase 3 melanoma trial involving 1,137 patients. The result gives Moderna its strongest late-stage evidence yet that its mRNA platform can work as a therapeutic cancer treatment. However, the detailed Phase 3 data have not been released, and investors should not confuse the new results with the 49% reduction in recurrence or death and 59% reduction in distant metastasis or death reported in the earlier Phase 2b study.
The clinical breakthrough arrived well before Moderna, Inc.'s (NASDAQ:MRNA) financial turnaround. The company generated $145 million of second-quarter 2026 revenue and reported a $782 million GAAP net loss, while continuing to target cash breakeven in 2028. It ended June with $6.9 billion of cash, cash equivalents, and investments, although it subsequently paid $950 million related to a litigation settlement.
The bear argument is that Moderna, Inc.'s (NASDAQ:MRNA) stock has repriced faster than the fundamental business has been proven. Its market value increased by tens of billions of dollars following the announcement of a trial whose detailed Phase 3 data remain outstanding. Regulatory approval is still required, while personalized cancer vaccines must overcome significant manufacturing and logistical challenges. Success in melanoma also does not guarantee comparable results in lung, bladder, kidney, or other cancers.
#mrna
7 days ago
A dramatic sporting moment frozen in time 70 years ago remains as popular as ever with football fans, and even inspired a statue.
One of the finest players of his era - Tom Finney of Preston North End - was photographed during a deluge at Chelsea's Stamford Bridge in August 1956.
Like a water-skier cutting through the wake of a speedboat, Finney somehow manages to stay upright and in control.
These days, there is little doubt that top-flight referees facing similar conditions would abandon the match.
But in August 1956, the Football League first division game - the equivalent of the Premier League - continued and the players were expected to roll their sleeves up and get on with it.
#players
One of the finest players of his era - Tom Finney of Preston North End - was photographed during a deluge at Chelsea's Stamford Bridge in August 1956.
Like a water-skier cutting through the wake of a speedboat, Finney somehow manages to stay upright and in control.
These days, there is little doubt that top-flight referees facing similar conditions would abandon the match.
But in August 1956, the Football League first division game - the equivalent of the Premier League - continued and the players were expected to roll their sleeves up and get on with it.
#players
7 days ago
Tuniu Corporation's (NASDAQ:TOUR) ADSs closed lower after the company reported its second-quarter results. Net revenue increased 3.0% year over year to RMB138.9 million, while packaged-tour revenue rose 6.8% to RMB121.1 million as organized tours continued to grow.
However, cost of revenue increased 27.9% to RMB62.5 million, substantially outpacing the top line. Gross profit declined 11.1% to RMB76.4 million, and gross margin contracted to 55.0% from 63.8%. Tuniu consequently swung to a RMB6.1 million operating loss from RMB7.1 million of operating income a year earlier.
Packaged-tour growth indicates that demand for Tuniu's core travel products remains intact. The company has been expanding small-group, private and customized tour offerings in response to demand for more personalized and flexible travel options.
Tuniu also remained marginally profitable below the operating line. GAAP net income attributable to ordinary shareholders was RMB0.7 million. Company-defined non-GAAP net income attributable to ordinary shareholders was RMB2.2 million after excluding share-based compensation and amortization of acquired intangible **** ets.
Liquidity provides additional room to absorb uneven travel demand. Tuniu ended June with approximately RMB1.0 billion in cash and cash equivalents, restricted cash, short-term investments, and long-term deposits. Management said during the earnings call that Tuniu generated RMB46.9 million of operating cash flow while recording RMB1.4 million of capital expenditures.
#tuniu #company #revenue #demand
However, cost of revenue increased 27.9% to RMB62.5 million, substantially outpacing the top line. Gross profit declined 11.1% to RMB76.4 million, and gross margin contracted to 55.0% from 63.8%. Tuniu consequently swung to a RMB6.1 million operating loss from RMB7.1 million of operating income a year earlier.
Packaged-tour growth indicates that demand for Tuniu's core travel products remains intact. The company has been expanding small-group, private and customized tour offerings in response to demand for more personalized and flexible travel options.
Tuniu also remained marginally profitable below the operating line. GAAP net income attributable to ordinary shareholders was RMB0.7 million. Company-defined non-GAAP net income attributable to ordinary shareholders was RMB2.2 million after excluding share-based compensation and amortization of acquired intangible **** ets.
Liquidity provides additional room to absorb uneven travel demand. Tuniu ended June with approximately RMB1.0 billion in cash and cash equivalents, restricted cash, short-term investments, and long-term deposits. Management said during the earnings call that Tuniu generated RMB46.9 million of operating cash flow while recording RMB1.4 million of capital expenditures.
#tuniu #company #revenue #demand
7 days ago
BioNTech SE (NASDAQ:BNTX) rallied following the first positive interim Phase 3 topline result for a personalized mRNA cancer therapy. Moderna and Merck said intismeran, combined with Keytruda, significantly improved recurrence-free and distant metastasis-free survival in patients with surgically removed high-risk melanoma. The result lifted other mRNA developers because it provided the strongest evidence yet that the technology can work against cancer in a large late-stage trial. For BioNTech SE (NASDAQ:BNTX), however, the rally raises a harder question: does validation of the therapeutic class meaningfully improve the odds for its own candidates, or has the market moved ahead of company-specific evidence?
The distinction matters. Moderna's intismeran is individually designed around mutations found in each patient's tumor. BioNTech SE (NASDAQ:BNTX) is awaiting an interim ******* ysis from the Phase 3 portion of AHEAD-MERIT, which tests BNT113 with pembrolizumab in first-line unresectable recurrent or metastatic HPV16-positive, PD-L1-positive head-and-neck squamous cell carcinoma. BNT113 is an off-the-shelf FixVac therapy encoding the HPV16 E6 and E7 oncoproteins. Different antigens, manufacturing approaches, cancer types and treatment settings prevent Moderna's result from functioning as a direct clinical read-through.
Still, BioNTech SE (NASDAQ:BNTX) has more than one attempt at building an oncology franchise. The company has 14 ongoing pivotal trials across mRNA immunotherapies, immunomodulators and antibody-drug conjugates. It expects three late-stage readouts during 2026, including the BNT113 interim ******* ysis, and ended June with €16.6 billion in cash, cash equivalents and security investments.
The bull case for BioNTech SE (NASDAQ:BNTX) is that Moderna and Merck have reduced skepticism around the broader platform. Their trial enrolled 1,137 patients and met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival, with no new safety concerns reported. The result shows that an mRNA therapy can add meaningful benefit to a checkpoint inhibitor in Phase 3.
BioNTech also has a personalized program that more closely resembles intismeran. Autogene cevumeran, partnered with Genentech, is being studied in randomized Phase 2 trials in pancreatic and colorectal cancer. Meanwhile, BNT113 has FDA Fast Track designation and could provide BioNTech's own pivotal mRNA evidence. The company's cash position gives it room to fund these programs and absorb failures elsewhere in the portfolio.
#biontech
The distinction matters. Moderna's intismeran is individually designed around mutations found in each patient's tumor. BioNTech SE (NASDAQ:BNTX) is awaiting an interim ******* ysis from the Phase 3 portion of AHEAD-MERIT, which tests BNT113 with pembrolizumab in first-line unresectable recurrent or metastatic HPV16-positive, PD-L1-positive head-and-neck squamous cell carcinoma. BNT113 is an off-the-shelf FixVac therapy encoding the HPV16 E6 and E7 oncoproteins. Different antigens, manufacturing approaches, cancer types and treatment settings prevent Moderna's result from functioning as a direct clinical read-through.
Still, BioNTech SE (NASDAQ:BNTX) has more than one attempt at building an oncology franchise. The company has 14 ongoing pivotal trials across mRNA immunotherapies, immunomodulators and antibody-drug conjugates. It expects three late-stage readouts during 2026, including the BNT113 interim ******* ysis, and ended June with €16.6 billion in cash, cash equivalents and security investments.
The bull case for BioNTech SE (NASDAQ:BNTX) is that Moderna and Merck have reduced skepticism around the broader platform. Their trial enrolled 1,137 patients and met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival, with no new safety concerns reported. The result shows that an mRNA therapy can add meaningful benefit to a checkpoint inhibitor in Phase 3.
BioNTech also has a personalized program that more closely resembles intismeran. Autogene cevumeran, partnered with Genentech, is being studied in randomized Phase 2 trials in pancreatic and colorectal cancer. Meanwhile, BNT113 has FDA Fast Track designation and could provide BioNTech's own pivotal mRNA evidence. The company's cash position gives it room to fund these programs and absorb failures elsewhere in the portfolio.
#biontech
7 days ago
Deutsche Bank Aktiengesellschaft (NYSE:DB) completed its €1 billion share-buyback program on August 21 after acquiring 35.7 million treasury shares, equivalent to 1.87% of its share capital. The shares were repurchased at a volume-weighted average price of €28. Treasury-share acquisition can reduce the shares used in per-share calculations while the shares remain in treasury, but it is distinct from legal cancellation.
Deutsche Bank Aktiengesellschaft (NYSE:DB) followed that program with a new buyback of up to €500 million starting August 25 and scheduled to end no later than December 11. The new program is the bank's first funded from current-year net profit. Management's 60% target refers to total dividends and buybacks as a percentage of net profit attributable to Deutsche Bank shareholders from 2026.
The earnings base currently supports the feasibility of that target. Deutsche Bank Aktiengesellschaft (NYSE:DB) reported second-quarter profit after tax of €1.9 billion, up 10% year over year, while first-half profit reached a record €4.1 billion. Quarterly net revenues increased 9% to €8.5 billion, with growth across all four businesses.
The capital position also suggests that Deutsche Bank Aktiengesellschaft (NYSE:DB) can execute the new program without moving outside management's operating range. Its Common Equity Tier 1 ratio was 13.9% at June 30 after deductions aligned with the 60% payout target. The bank said the €500 million program was already fully covered by existing capital deductions.
For Deutsche Bank Aktiengesellschaft (NYSE:DB), the completed purchases carry more weight than an unused authorization. Completion of the new program would bring buybacks conducted during 2026 to €1.5 billion, compared with €1 billion in 2025. The first €1 billion program related to the prior capital-return cycle, while the new €500 million program is the first funded from 2026 earnings.
#bank #deutsche
Deutsche Bank Aktiengesellschaft (NYSE:DB) followed that program with a new buyback of up to €500 million starting August 25 and scheduled to end no later than December 11. The new program is the bank's first funded from current-year net profit. Management's 60% target refers to total dividends and buybacks as a percentage of net profit attributable to Deutsche Bank shareholders from 2026.
The earnings base currently supports the feasibility of that target. Deutsche Bank Aktiengesellschaft (NYSE:DB) reported second-quarter profit after tax of €1.9 billion, up 10% year over year, while first-half profit reached a record €4.1 billion. Quarterly net revenues increased 9% to €8.5 billion, with growth across all four businesses.
The capital position also suggests that Deutsche Bank Aktiengesellschaft (NYSE:DB) can execute the new program without moving outside management's operating range. Its Common Equity Tier 1 ratio was 13.9% at June 30 after deductions aligned with the 60% payout target. The bank said the €500 million program was already fully covered by existing capital deductions.
For Deutsche Bank Aktiengesellschaft (NYSE:DB), the completed purchases carry more weight than an unused authorization. Completion of the new program would bring buybacks conducted during 2026 to €1.5 billion, compared with €1 billion in 2025. The first €1 billion program related to the prior capital-return cycle, while the new €500 million program is the first funded from 2026 earnings.
#bank #deutsche
7 days ago
Deja Kelly wasn't sure what to expect when she signed with the Charlotte Crown back in May.
After playing her college ball at Oregon and North Carolina, Kelly spent some time in training camp with the Las Vegas Aces in 2025, played in Athletes Unlimited last winter, and also worked in television for the Big Ten Network. As summer approached, she wanted to keep playing basketball, but knew options were limited - especially if she wanted to play in the U.S. where her friends and family could watch her.
Then the Upshot League started, of which the Crown are one of four teams in its inaugural season. Founded by former WNBA president Donna Orender and backed by Zawyer Sports and Entertainment, the Upshot League sought to fill a gap in the U.S. women's basketball ecosystem by providing an environment in which the players squeezed out by the WNBA's limited roster sizes could still play team basketball, develop their skills and get paid for it.
While not affiliated with the WNBA, a simple way of thinking about the Upshot League is that it's the women's basketball equivalent of the NBA's G League.
"Whenever you're part of something for the first time, it's kind of nerve-wracking because it could be all over the place. It could go either way," Kelly told USA TODAY Sports. "I think overall, once we ironed out all the wrinkles, this is really high-level basketball. The talent level is there, so it's really good competition every single night. That's something that definitely exceeded my expectations.
#kelly #sports #playing
After playing her college ball at Oregon and North Carolina, Kelly spent some time in training camp with the Las Vegas Aces in 2025, played in Athletes Unlimited last winter, and also worked in television for the Big Ten Network. As summer approached, she wanted to keep playing basketball, but knew options were limited - especially if she wanted to play in the U.S. where her friends and family could watch her.
Then the Upshot League started, of which the Crown are one of four teams in its inaugural season. Founded by former WNBA president Donna Orender and backed by Zawyer Sports and Entertainment, the Upshot League sought to fill a gap in the U.S. women's basketball ecosystem by providing an environment in which the players squeezed out by the WNBA's limited roster sizes could still play team basketball, develop their skills and get paid for it.
While not affiliated with the WNBA, a simple way of thinking about the Upshot League is that it's the women's basketball equivalent of the NBA's G League.
"Whenever you're part of something for the first time, it's kind of nerve-wracking because it could be all over the place. It could go either way," Kelly told USA TODAY Sports. "I think overall, once we ironed out all the wrinkles, this is really high-level basketball. The talent level is there, so it's really good competition every single night. That's something that definitely exceeded my expectations.
#kelly #sports #playing
8 days ago
Alongside boosting exploration and production offshore its home market Norway, Equinor is pursuing an international growth strategy, aiming to significantly increase its overseas oil and gas output by focusing on fewer but more lucrative regions such as the U.S., Brazil, and Angola.
In recent years, Equinor has streamlined and high-graded its portfolio outside Norway, selling ****** ets and positions in Azerbaijan and Nigeria, to name a few.
But Equinor has kept and grown its U.S., Brazilian, and Angolan businesses, and plans to keep these growing through 2030, the company's executives said at the Offshore Northern Seas (ONS) energy conference in Stavanger this week.
Equinor's international production averaged 750,000 barrels of oil equivalent per day (boepd) in the second quarter of 2026. The company expects to raise this to 950,000 boepd by 2030, by boosting the U.S., Brazilian, and Angolan output, executive vice president Philippe Mathieu said at a press briefing in Stavanger on Tuesday.
"Equinor's international oil and gas portfolio is simplified, improved and set for significant growth," Mathieu said.
#offshore #boosting
In recent years, Equinor has streamlined and high-graded its portfolio outside Norway, selling ****** ets and positions in Azerbaijan and Nigeria, to name a few.
But Equinor has kept and grown its U.S., Brazilian, and Angolan businesses, and plans to keep these growing through 2030, the company's executives said at the Offshore Northern Seas (ONS) energy conference in Stavanger this week.
Equinor's international production averaged 750,000 barrels of oil equivalent per day (boepd) in the second quarter of 2026. The company expects to raise this to 950,000 boepd by 2030, by boosting the U.S., Brazilian, and Angolan output, executive vice president Philippe Mathieu said at a press briefing in Stavanger on Tuesday.
"Equinor's international oil and gas portfolio is simplified, improved and set for significant growth," Mathieu said.
#offshore #boosting
8 days ago
Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Achieved a 20% quarter-over-quarter increase in EBITDA equivalent cash flow, primarily driven by two Suezmax tankers operating in a high-rate spot market environment.
Capitalized on a 'booming' tanker market where Suezmax spot rates reached $133,000 per day, significantly exceeding the previous long-term charter rate of $30,000 per day.
Expanded the car carrier portfolio through the order of four dual-fuel newbuildings and new three-year charters for older vessels, adding $233 million to the firm backlog.
Maintained high fleet utilization across shipping segments, with container, car carrier, and tanker segments all operating at 99.3% or higher.
#operating #market #tanker
Achieved a 20% quarter-over-quarter increase in EBITDA equivalent cash flow, primarily driven by two Suezmax tankers operating in a high-rate spot market environment.
Capitalized on a 'booming' tanker market where Suezmax spot rates reached $133,000 per day, significantly exceeding the previous long-term charter rate of $30,000 per day.
Expanded the car carrier portfolio through the order of four dual-fuel newbuildings and new three-year charters for older vessels, adding $233 million to the firm backlog.
Maintained high fleet utilization across shipping segments, with container, car carrier, and tanker segments all operating at 99.3% or higher.
#operating #market #tanker
9 days ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was up 7.5% in after-hours trading as of approximately 5:33 p.m. ET Wednesday after the FDA approved Genglycos for glycogen storage disease type Ia, or GSDIa. The one-time gene therapy is the first approved treatment designed to address the disorder's underlying cause. It will carry a U.S. list price of approximately $2.7 million per patient and is expected to become available through qualified treatment centers within 30 to 60 days.
The approval gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) first-mover status in a disease the company estimates affects only 1,500 to 2,500 Americans. The commercial question is whether a high-priced treatment for an ultra-rare population can produce meaningful revenue after diagnosis, reimbursement, and treatment-center constraints.
GSDIa prevents the liver from releasing glucose properly, leaving patients dependent on frequent raw-cornstarch doses to avoid potentially life-threatening hypoglycemia. In the Phase 3 GlucoGene trial, Genglycos reduced mean daily cornstarch intake by 41% at Week 48, compared with 10% for placebo, while maintaining glucose control. For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), reducing that daily burden creates a clear argument for premium pricing.
Longer-term data also support the treatment's potential durability. At Week 96, the original-treatment group reported a 61% mean reduction from baseline, while the crossover group reported a 61% reduction from Week 48, when it began treatment. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will manufacture the therapy at its Bedford, Massachusetts, facility, giving the company direct control over an important part of the supply chain.
The launch will also test infrastructure that could support future gene therapies. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) already sells rare-disease products including Crysvita, Dojolvi, Evkeeza and Mepsevii. Second-quarter revenue reached $214 million, while cash, cash equivalents, and marketable securities totaled $436 million as of June 30. Genglycos therefore enters a functioning commercial organization rather than a first-time launch platform.
#rare #pharmaceutical
The approval gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) first-mover status in a disease the company estimates affects only 1,500 to 2,500 Americans. The commercial question is whether a high-priced treatment for an ultra-rare population can produce meaningful revenue after diagnosis, reimbursement, and treatment-center constraints.
GSDIa prevents the liver from releasing glucose properly, leaving patients dependent on frequent raw-cornstarch doses to avoid potentially life-threatening hypoglycemia. In the Phase 3 GlucoGene trial, Genglycos reduced mean daily cornstarch intake by 41% at Week 48, compared with 10% for placebo, while maintaining glucose control. For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), reducing that daily burden creates a clear argument for premium pricing.
Longer-term data also support the treatment's potential durability. At Week 96, the original-treatment group reported a 61% mean reduction from baseline, while the crossover group reported a 61% reduction from Week 48, when it began treatment. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will manufacture the therapy at its Bedford, Massachusetts, facility, giving the company direct control over an important part of the supply chain.
The launch will also test infrastructure that could support future gene therapies. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) already sells rare-disease products including Crysvita, Dojolvi, Evkeeza and Mepsevii. Second-quarter revenue reached $214 million, while cash, cash equivalents, and marketable securities totaled $436 million as of June 30. Genglycos therefore enters a functioning commercial organization rather than a first-time launch platform.
#rare #pharmaceutical
9 days ago
Debt by any other name is still debt, and if you've ever been in any amount of it, you'll know that the one thing that is definitely not the solution is, well, even more debt. And yet, that seems to be the preferred strategy of modern governments: If more money is needed, then they can simply fund it with endless debt.
The level of arrears accrued by the powers of the world is almost incomprehensible at this point. According to the Institute of International Finance, total global debt, across sectors and types of lending, is over $350 trillion, equivalent to about 305% of global GDP. That's compared to 240% of GDP in 2005.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
#debt #dave
The level of arrears accrued by the powers of the world is almost incomprehensible at this point. According to the Institute of International Finance, total global debt, across sectors and types of lending, is over $350 trillion, equivalent to about 305% of global GDP. That's compared to 240% of GDP in 2005.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
#debt #dave
9 days ago
Billionaire Ray Dalio warned last week that the U.S. is heading for a major debt crisis, likening the nation to a person on the verge of a heart attack.
The Bridgewater ***** ociates founder wrote in an August 21 LinkedIn post that a $4 billion U.S. debt buyback, combined with rising bond yields, a weak dollar and a ***** anese sell-off of U.S. bond holdings all point to a potential government debt crisis, which can result in "the equivalent of an economic heart attack that comes when the constriction of debt-financed spending shuts down the normal flow of the economic circulatory system."
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
#debt #crisis #heart #attack
The Bridgewater ***** ociates founder wrote in an August 21 LinkedIn post that a $4 billion U.S. debt buyback, combined with rising bond yields, a weak dollar and a ***** anese sell-off of U.S. bond holdings all point to a potential government debt crisis, which can result in "the equivalent of an economic heart attack that comes when the constriction of debt-financed spending shuts down the normal flow of the economic circulatory system."
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
#debt #crisis #heart #attack
9 days ago
Opera Limited (NASDAQ:OPRA) moved its second-quarter earnings release from August 25 to August 19, focusing attention on whether another guidance increase is coming. First-quarter revenue rose 23% to $175.8 million, while adjusted EBITDA increased 30% to $42.0 million. Both exceeded the company's guidance, and the shares gained 5.3% following the report.
The financial momentum has been accompanied by faster adoption in valuable Western markets. Opera Limited (NASDAQ:OPRA) said combined MAUs for its Android and iOS browsers increased 66% year over year in the U.K. and 40% in the U.S. during the second quarter. Its built-in AI can search, answer questions, and generate content without requiring users to leave the browser.
The question is whether Opera Limited (NASDAQ:OPRA) is building a durable AI-browser franchise or simply finding better ways to monetize traffic through advertising and search partners.
Opera Limited (NASDAQ:OPRA) entered the second quarter with encouraging operating leverage. Average monthly active users reached 288 million in the first quarter, up four million sequentially, while annualized revenue per user increased 25% year over year to $2.43. Adjusted EBITDA grew faster than revenue, and free cash flow from operations nearly tripled to $35.5 million.
Opera Limited (NASDAQ:OPRA) also raised its full-year outlook after exceeding first-quarter guidance. The company projected revenue of $727 million to $740 million and adjusted EBITDA of $170 million to $174 million. Its second-quarter forecast called for revenue growth of 23% to 25% and adjusted EBITDA of $40 million to $42 million, equivalent to a 23% margin at the midpoints.
#quarter #limited #ebitda #adjusted
The financial momentum has been accompanied by faster adoption in valuable Western markets. Opera Limited (NASDAQ:OPRA) said combined MAUs for its Android and iOS browsers increased 66% year over year in the U.K. and 40% in the U.S. during the second quarter. Its built-in AI can search, answer questions, and generate content without requiring users to leave the browser.
The question is whether Opera Limited (NASDAQ:OPRA) is building a durable AI-browser franchise or simply finding better ways to monetize traffic through advertising and search partners.
Opera Limited (NASDAQ:OPRA) entered the second quarter with encouraging operating leverage. Average monthly active users reached 288 million in the first quarter, up four million sequentially, while annualized revenue per user increased 25% year over year to $2.43. Adjusted EBITDA grew faster than revenue, and free cash flow from operations nearly tripled to $35.5 million.
Opera Limited (NASDAQ:OPRA) also raised its full-year outlook after exceeding first-quarter guidance. The company projected revenue of $727 million to $740 million and adjusted EBITDA of $170 million to $174 million. Its second-quarter forecast called for revenue growth of 23% to 25% and adjusted EBITDA of $40 million to $42 million, equivalent to a 23% margin at the midpoints.
#quarter #limited #ebitda #adjusted
9 days ago
On Tuesday, Lego posted a record first-half of 41.9 billion Danish kroner, or roughly $6.5 billion, in revenue — up 21% from the same period in 2025. In constant currency terms, revenue grew 26%.
The company said operating profit climbed 22% to reach 10.9 billion Danish kroner, equivalent to around $1.7 billion. Net profit climbed 32% to 8.6 billion Danish kroner. Consumer sales grew 22%, driven by demand across the product range. The company said it outpaced the global toy market and gained market share.
CEO Niels B. Christiansen said the results reflected broad appeal across the portfolio. "Our portfolio of products offers something for everyone, and culturally relevant brand experiences continue to drive demand across the globe," Christiansen said in a statement.
In the first half of the year, Lego introduced 332 new sets. Bestselling themes included Speed Champions, Botanicals, Technic, Icons and Star Wars. The company also introduced its LEGO SMART Play platform, which brings sensor-based interactive features to brick sets, and debuted a partnership with Pokémon. Sporting partnerships tied to Formula 1, the FIFA World Cup 2026 and K-pop property KPop Demon Hunters also contributed to consumer demand.
Christiansen told CNBC that new partnerships draw in consumers who had not previously found their interests represented in the Lego brand. "We've also seen that we retain consumers really, really well, and we're selling more to those we have," he said.
#danish #christiansen #kroner
The company said operating profit climbed 22% to reach 10.9 billion Danish kroner, equivalent to around $1.7 billion. Net profit climbed 32% to 8.6 billion Danish kroner. Consumer sales grew 22%, driven by demand across the product range. The company said it outpaced the global toy market and gained market share.
CEO Niels B. Christiansen said the results reflected broad appeal across the portfolio. "Our portfolio of products offers something for everyone, and culturally relevant brand experiences continue to drive demand across the globe," Christiansen said in a statement.
In the first half of the year, Lego introduced 332 new sets. Bestselling themes included Speed Champions, Botanicals, Technic, Icons and Star Wars. The company also introduced its LEGO SMART Play platform, which brings sensor-based interactive features to brick sets, and debuted a partnership with Pokémon. Sporting partnerships tied to Formula 1, the FIFA World Cup 2026 and K-pop property KPop Demon Hunters also contributed to consumer demand.
Christiansen told CNBC that new partnerships draw in consumers who had not previously found their interests represented in the Lego brand. "We've also seen that we retain consumers really, really well, and we're selling more to those we have," he said.
#danish #christiansen #kroner
